The incidence of lymphoma ranks among the top five malignant neoplasms. 1 Extranodal lymphomas, however, comprise a minority of cases: approximately 25–40%, depending on the criteria used. 2 Lymphomas ...

Previous studies have demonstrated an increased risk of cutaneous melanoma (CM) after lymphoid neoplasms (LNs), such as chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). 1,2 Now, a ...

Patients with a history of cutaneous melanoma are at increased risk of developing lymphoid neoplasms and vice versa. This study found that these risks differ by subtype of lymphoid neoplasm and that ...

The findings come from the group’s review of over 30 years’ worth of research of the presence of autoimmune cytopenias and autoimmune diseases in lymphoid and myeloid neoplasms. Autoimmune ...

Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors. A new integrative, capture-based, next-generation ...

The FDA Friday approved pemigatinib (Pemazyre), a selective fibroblast growth factor (FGFR) inhibitor, to treat adults who have relapsed or refractory (R/R) myeloid/lymphoid neoplasms (MLNs) with ...

This is a preview. Log in through your library . Abstract A multi-centre hospital-based case-control study was conducted in three regions of France between 2000 and 2003 in order to establish the risk ...

Philadelphia, July 29, 2021 – Increasing knowledge about genomic biomarkers has facilitated better monitoring and personalized management of patients with B-cell malignant tumors. A new integrative, ...

The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement. The Food and Drug Administration (FDA) ...

Purpose: Results from studies of smoking and non-Hodgkin lymphoid neoplasms (NHL) are inconsistent. This study assessed whether this inconsistency might be due to the heterogeneous nature of the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and ...